Modular Medical (MODD) Drops -57% in 30 Days as Commercial Momentum Slows
Key Takeaways
- Modular Medical (MODD) closed at $1.87 on August 13, 2026, down approximately 57% from the $4.31 closing price recorded 30 calendar days earlier on July 14, 2026.
- The decline has pushed the stock toward the lower end of its 52-week range of $1.74–$30.00 and well below its 50-day moving average near $3.64.
- The sell-off followed a period of commercial-launch momentum, including FDA 510(k) clearance for the Pivot tubeless insulin patch pump in April 2026, that had lifted shares earlier in the year.
- Modular Medical remains essentially pre-revenue, with a trailing twelve-month net loss of about $28.2 million and roughly $6.9 million in cash as of its most recent quarter, keeping funding and dilution risk in focus.
- Heavy volume on August 13 and an increase in short interest to approximately 214,000 shares reflect fragile near-term sentiment.
Company Overview and Market Position
Modular Medical, Inc. (NASDAQ: MODD) is a San Diego-based medical device company focused on insulin delivery technology. Its flagship product, the Pivot tubeless insulin patch pump, is designed for adults with type 1 and type 2 diabetes who use multiple daily injections. The company positions Pivot around simplicity and accessibility, targeting a large population of insulin users who have not adopted traditional pumps. After receiving FDA 510(k) clearance in April 2026, Modular Medical transitioned from a development-stage business into an early commercial-stage company, and investors now follow the stock primarily for launch execution, payer traction, manufacturing scale-up, and cash runway. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 calendar days ended August 13, 2026, MODD declined from a closing price of $4.31 on July 14 to $1.87, a drop of roughly 56.6%. The move was not a single-day event: the stock recorded sharp single-session declines on July 16 (-22.7%), July 24 (-17.4%), and August 13 (-9.7%), with the August 13 decline occurring on volume of about 1.6 million shares compared with an average closer to 129,000.
The weakness extends beyond the 30-day window. Over the trailing three months, MODD has fallen approximately 44.5% from a closing price of $3.37 on May 15. Year to date, the stock is down about 83% from $10.92 at the end of 2025, underscoring a sustained downtrend despite positive product-related milestones. From what I see, this kind of sustained pressure often warrants a closer look at volume patterns and short interest trends.
What Drove the Stock in the Last 30 Days
Early in the period, MODD benefited from a series of verified commercial updates, including the start of Pivot shipments to endocrinology practices, initial patient insulin deliveries, a pilot program with IMO Health to identify eligible patients through electronic health records, and the formation of a Pivot Innovation Council. Those announcements supported a late-June advance, with the stock trading as high as $5.81 intraday on June 26.
That optimism faded in mid-July as investors refocused on fundamentals. Modular Medical is still generating essentially no revenue while posting a trailing twelve-month net loss near $28.2 million. With about $6.9 million in cash as of its most recent quarter and negative operating cash flow, the company faces recurring questions about future capital raises and shareholder dilution. A $3.4 million registered direct offering priced at $4.50 per share in April 2026, along with earlier financing activity, kept those concerns in the foreground. The resulting selling pressure appeared amplified by risk-off sentiment in micro-cap healthcare names, with down days occurring on above-average volume and short interest rising from roughly 162,000 to about 214,000 shares.
What Drove Performance Over the Last Quarter
The broader three-month decline reflects a market repricing of an early commercial-stage medical device company that has achieved regulatory clearance but has yet to demonstrate revenue or a clear path to profitability. Positive developments included FDA clearance for Pivot, the first commercial shipments, manufacturing preparations, and new clinical-commercial partnerships. These were offset by ongoing cash burn, a 1-for-30 reverse stock split completed at the end of March 2026, a workforce reduction announced in March 2026 to lower operating expenses, and dilutive financing transactions. The result was a quarter in which improving commercialization news was outweighed by financing overhang, execution uncertainty, and weak sentiment toward pre-revenue small-cap medical technology stocks. One thing that stands out is how quickly sentiment can shift once execution risks come back into focus.
What Investors Should Watch Next
The most important factors for MODD going forward include the pace of Pivot commercial adoption, physician training, patient onboarding, and early repeat ordering. Reimbursement and payer coverage discussions will be critical, as will results from the IMO Health electronic health record pilot. Investors should also monitor the FDA’s response to the software enhancements the company has submitted for Pivot, along with any updates on manufacturing capacity and gross margin trajectory. The next quarterly earnings release and management commentary on cash runway will be closely watched, particularly for signals about future financing needs. Finally, Nasdaq listing compliance and the stock’s ability to hold above the $1.00 minimum bid threshold remain relevant risk factors amid a competitive insulin pump market. I’m watching this closely for any signs of stabilization in the coming weeks.
Exploring Quantitative Trading Tools
In my research process, I sometimes review Tickeron’s Trending AI Robots page to see which automated strategies are gaining attention across different market conditions. It offers a practical way to compare trading styles and timeframes without relying on a single approach, which can add useful context when evaluating names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsContributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
MODD's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for MODD moved out of oversold territory on August 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 40 similar instances when the indicator left oversold territory. In of the 40 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MODD just turned positive on August 07, 2026. Looking at past instances where MODD's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MODD advanced for three days, in of 199 cases, the price rose further within the following month. The odds of a continued upward trend are .
MODD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for MODD crossed bearishly below the 50-day moving average on July 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MODD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MODD entered a downward trend on August 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.769) is normal, around the industry mean (11.053). P/E Ratio (0.000) is within average values for comparable stocks, (73.178). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.988). MODD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (0.000) is also within normal values, averaging (31.009).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MODD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement